| GTO ID | GTC3378 |
| Trial ID | NCT05783206 |
| Disease | COVID-19 |
| Altered gene | RdRp |
| Therapeutic/Target gene | Target gene |
| Therapy | siRNA |
| Treatment | MIR 19|siR-7-EM/KK-46 |
| Co-treatment | paracetamol |
| Phase | Phase2|Phase3 |
| Recruitment status | Completed |
| Title | Open Multicenter Controlled Clinical Trial to Evaluate Safety and Efficacy of Aerosolized MIR 19 Inhalation in Adult Outpatients With Mild COVID-19. |
| Year | 2022 |
| Country | Russian Federation |
| Company sponsor | National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia |
| Other ID(s) | 04-SiCoV/KK46-01/22 |
| Cohort1: MIR 19 | |||||||||
|
|||||||||
| Cohort2: Standard COVID-19 therapy | |||||||||
|
|||||||||